<?xml version="1.0" encoding="UTF-8"?>
<p>Glucocorticoid (GC) use in patients with HBV infection was known to relate to HBVr as early as the 1970s,
 <sup>
  <xref rid="bibr18-1759720X20912646" ref-type="bibr">18</xref>
 </sup> although its reported incidence varies significantly in the published literature (4–50%). The proposed pathophysiological mechanism seems to be twofold: GCs suppress T-cell cytotoxic function, thus diminishing the host’s immune check on the virus, but also directly stimulate HBV-DNA replication by activating a GC-responsive transcriptional regulatory element in the HBV genome.
 <sup>
  <xref rid="bibr17-1759720X20912646" ref-type="bibr">17</xref>,
  <xref rid="bibr19-1759720X20912646" ref-type="bibr">19</xref>
 </sup>
</p>
